Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Head and Neck Cancer
DRUG: Retifanlimab|DRUG: INCAGN02385|DRUG: INCAGN02390|DRUG: Placebo
Progression Free Survival (PFS), Defined as the interval between the date of first dose of study treatment and the earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death due to any cause., Up to 24 months
Objective Response Rate (ORR), Defined as having a Complete Response (CR) or Partial Response (PR), determined based on investigator assessment per RECIST v1.1., Up to 24 months|Duration of Response (DOR), Defined as the time from earliest date of disease response (CR or PR) until earliest date of disease progression, based on investigator assessment per RECIST v1.1, or death from any cause if occurring sooner than progression., Up to 24 months|Disease Control Rate (DCR), Defined as having CR, PR, or SD (≥ 6 months) as best response, based on investigator assessment per RECIST v1.1., Up to 24 months|Overall Survival (OS), Defined as the interval between the date of the date of first dose of study treatment until death due to any cause., Up to 36 months|Participants with treatment-emergent adverse events (TEAE), TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug, Up to 24 months
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).